Parsing MDS data

Parsing MDS data

Vidaza Ph III (Pharmion)
Arm Patients Remission rates Time to death or AML (months) Tx-related deaths
Vidaza azacitidine 89 CR: 5.6% (5) PR: 10.1% (9) OR: 15.7% (14) (p<0.0001) 21 (p<0.007) 1
Standard of care 83 0% 12 0
Primary endpoint was response rate. Complete response was defined by

Read the full 520 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE